D-0727-2022 Class III Terminated
FDA drug recall D-0727-2022 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Feb 25, 2022 and is designated Class III. Reason for recall: Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample The recall status is terminated (terminated Sep 9, 2024). Affected quantity: 768 tubes.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 6, 2022
- Initiation Date
- Feb 25, 2022
- Termination Date
- Sep 9, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 768 tubes
Product description
Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0.05%,15 g tubes, Rx only, Manufactured by: Taro Pharmaceuticals Industries Ltd. Haifa Bay, Israel 2624761, Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4048-1
Reason for recall
Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample
Distribution pattern
Product was distributed to one retail consignee in NY.
Code information
Lot #: AC33883, Exp. Date June 2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0727-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026